Condition
Immunoglobulin A Nephropathy (IgAN)
Total Trials
5
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 2 (3)
P 3 (1)
Trial Status
Recruiting3
Not Yet Recruiting1
Enrolling By Invitation1
Clinical Trials (5)
Showing 5 of 5 trials
NCT06935357Phase 3RecruitingPrimary
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT07522099Phase 2RecruitingPrimary
Chinese Adults With Kidney Disease
NCT07146906Phase 2RecruitingPrimary
A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
NCT07474636Phase 2Not Yet Recruiting
Efficacy and Safety Study of HS-10542 for IgA Nephropathy
NCT07135219Early Phase 1Enrolling By InvitationPrimary
A Study of Cizutamig in Patients With Immunoglobulin A Nephropathy
Showing all 5 trials